This large and complex expansion of a biologic medicine manufacturing plant increased capacity 75% by adding three production bioreactors, each 15,400 liters, as well as associated seed reactors and expanded warehouse cold rooms, freezers and central utilities.
Whether campaigning for President Obama or supporting stem cell research, Bob Clark, founder and executive chairman of contractor Clayco has never shied away from speaking his mind.
U.S. production facilities for COVID-19 vaccines nearing approval for Pfizer, Moderna and Johnson & Johnson are delivered by EPC contractors. But supply chain availability has been a tricky process.